1.	Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Phase: Phase IV Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: CHOP-Z, NCT01418430
2.	Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000269672, DFCI-99279, RPCI-DS-0218, ROCHE-RPCI-DS-0218, NCT00053976
3.	Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000064351, BIDMC-92020534, NEDH-92020534, BIDMC-FDR001054, NCI-H95-0732, NCT00002681
4.	Phase I/II Pilot Study of Anti-Tac Antibody Immunotherapy in Adults with Tac-Positive T-Cell Leukemia/Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-83-C-23, NCI-T84-0153N
5.	Phase I/II Preliminary Feasibility Study of Immunotherapy with Pseudomonas Conjugated Anti-Tac Antibody for Adult T-Cell Leukemia/Lymphoma (Summary Last Modified 08/89) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-85-C-91, NCI-T85-0147N, T85-0147
6.	Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000579573, R21CA132891, DUMC-PRO00000947, PRO00000947, DUMC-SPORE II 2003 CMV Grant, NCT00626015
7.	Daclizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia Phase: Phase II, Phase I Type: Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000579683, P50CA108786, P30CA014236, DUMC-PRO00000581, SPORE Project 3, Pro00000581, NCT00626483
8.	Phase II Study of 90Y-Humanized Anti-Tac for Tac-Expressing Post-Thymic T-Cell Malignancies Other Than Adult T-Cell Leukemia (Summary Last Modified 06/97) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-94-C-0068D
9.	Anti-Tac for Treatment of Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 10 and over Sponsor: NCI Protocol IDs: 000030, 00-C-0030, NCI-00-C-0030, NCT00020020, NCT00001941
10.	Phase II Study of Nonmyeloablative Conditioning Regimen Followed by HLA Matched Sibling Donor Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies (Summary Last Modified 01/2002) Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: MSGCC-0012, NCI-V00-1624, NCT00006350
11.	Phase II Study of Yttrium-90-Labeled Humanized Anti-Tac MOAB in Patients with Tac-Expressing Adult T-Cell Leukemia/Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-93-C-0066F
12.	Phase I Study of Yttrium 90 Labeled Monoclonal Antibody Anti-Tac in Patients With Tac Expressing Cutaneous T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-90-C-43A
13.	Phase I Study of Single Intravenous Doses of Humanized Anti-Tac (Ro 24-7375) in Patients with Tac-Bearing Malignancies (Summary Last Modified 06/1999) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-92-C-0046, NCI-T91-0276N, T91-0276